NEWS
Our Research in the Media: Deník.cz on Our Work in Atopic Eczema
Read what they wrote about us. In a new article and an interview with our CEO, we discuss our research...
AUMED, a.s. Received Support for the Project “PhageBiome-N – Development of an innovative phage and probiotic formulation for the elimination of Staphylococcus aureus strains, including MRSA, and stabilization of the nasal microbiome for use in infection prevention and treatment.”
AUMED, a.s. is launching a project titled PhageBiome-N, which has received support under the Operational Programme Technologies and Applications for...
A Century-Long Tradition of Czech Immunology and Vaccination: From the Institute of Sera and Vaccines (ÚSOL) to AUMED, a.s.
The Beginnings and Establishment of the State Health Institute (SZÚ) AUMED, a.s. is the proud successor to an almost century-long...
AUMED, a.s. successfully participated in the immunology congress
AUMED representatives participated in the XL. Congress of Slovak and Czech allergists and clinical immunologists, which took place from October...
AUMED, a.s. Received Support for the Project “Development of an Immunization Product for Protection Against the Causative Agent of Whooping Cough”
AUMED has received support for the project titled “Development of an Immunization Product for Protection Against the Causative Agent of...
AUMED, a.s. has received support for the project “Innovation in the Production of Immunological Preparations”
AUMED has received support for the project “Innovation in the Production of Immunological Preparations,” registration number CZ.01.01.01/02/24_051/0004982. The essence of...
AUMED Pharma a.s., is expanding the Phage Glow range!
Our subsidiary, AUMED Pharma a.s., is expanding the Phage Glow range with two new product lines: ATOPCARE Atopcare is here...
AUMED, a.s. has received permission for a clinical trial, phase III, of the medicinal product TFI
Based on the submitted application and the supplied documents, the State Institute for Drug Control (Czech Republic) has authorized a...
AUMED, a.s. successfully completed a clinical trial, phase I, of the medicinal product TFI
AUMED, a.s. completed a clinical trial, phase I, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral...
AUMED, a.s. presented current research at the 45th ICMM World Congress on Military Medicine
AUMED representatives participated in the 45th ICMM World Congress on Military Medicine held in Brisbane, Australia. At the congress, AUMED...
AUMED, a.s. presented phage research at the Viruses of Microbes 2024 conference in Cairns, Australia
AUMED representatives participated in the prestigious conference Viruses of Microbes 2024, which was held in the city of Cairns, Australia....
Phage Glow Bioactive acne gel in new packaging
Now you can order Phage Glow Bioactive acne gel in a new package. This revolutionary beauty product based on phage...
Aumed Pharma a.s. launches the new Phage Glow Skin Spray
Our subsidiary Aumed Pharma a.s. launches a special bioactive gel intended for eczematous skin Phage Glow Skin Spray – a...
New workplace BENÁTKY n/J.
AUMED, a.s. at the beginning of 2024 opened a new workplace at the address 5. května 301, 294 71 Benátky...
Aumed Pharma a.s. launches new food supplement Gut Guard
Our subsidiary Aumed Pharma a.s. launches food supplement Gut Guard. Gut Guard probiotics contain a combination of 13 vital probiotic...
AUMED, a.s. received support for the development of a preparation with phages for recurrent bacterial vaginosis
AUMED received support for the project “Development of an antibacterial preparation with phages for recurrent bacterial vaginosis”, registration number CZ.01.01.01/01/22_002/0000523....
AUMED, a.s. received support for the development of a vaccine against Staphylococcus aureus
AUMED received support for the project “Development of a new vaccine against Staphylococcus aureus”, registration number CZ.01.01.01/01/22_002/0000585. Staphylococcus aureus causes...
AUMED, a.s. received support for the development of a product for the supportive treatment of the skin in the case of atopic eczema
AUMED received support for the project “Development of a preparation based on a cleansing spray intended for the supportive treatment...
AUMED participated in the immunology congress with great success
Representatives of AUMED participated in the XL. Congress of Slovak and Czech allergists and clinical immunologists, which took place in...
AUMED, a.s. successfully completed the project “Comparison of the effectiveness of three different batches of leukocyte extract with transfer factor activity (TFI) in the form of fast-dissolving tablets”
AUMED, a.s. successfully completed the project “Comparison of the effectiveness of three different batches of leukocyte extract with transfer factor...
A revolution in the fight against problematic skin
Our subsidiary Aumed Pharma a.s. is launching a revolutionary bacteriophage-based product in the fight against problematic skin. Phage Glow is...
The new website of our subsidiary Aumed Pharma a.s.
Our subsidiary Aumed Pharma is launching a new website (www.aumedpharma.cz) where you can purchase our specially developed nutritional supplements and...
AUMED joins the association fighting against antibiotic resistance
A representative of AUMED participated in the meeting to establish the association Czech Antibiotic Resistance Platform (CZEPAR). The course of...
AUMED, a.s. successfully completed the project entitled “Transfer factor TFI – Medicinal product”
AUMED, a.s. successfully completed the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As part of the project,...
AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”
AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As...
AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford
AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a...
AUMED a.s. founded a new company AUMED Immunology a.s.
AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company....
Successful completion of the TRIO project „Development of a new dosage form for oral vaccine administration”
AUMED, a.s. successfully completed a multi-year project of the research and development support program of the Ministry of Industry and...
AUMED, a.s. received a grant for the Innovation Project entitled “TFI Transfer Factor – Medicine”
AUMED, a.s. received a grant in the Operational Program Enterprise and Innovation for Competitiveness under the Innovation Call – Innovation...
PCR GARGLING KIT
AUMED, a.s. launches its own self-sampling set based on the principle of gargling of the oral cavity and pharynx. The...
AUMED a.s. received support for the production of a diagnostic kit for covid-19
AUMED a.s. received support for the project PRODUCTION OF DIAGNOSTIC KIT FOR COVID-19 ON THE LAMP PRINCIPLE within the TECHNOLOGY...
New sampling set GARGTEST
AUMED, a.s. collaborated on the development of a new self-sampling set based on the principle of gargling of the oral...
“COVID-19” TESTING FOR COMPANIES
AUMED a.s. offers for companies a comprehensive solution for preventive testing of the SARS-CoV-2 virus (COVID-19). We provide sampling and...
Covid-19 diagnostics using a newly developed test – AUMED test RT-LAMP Assay SARS-CoV-2
AUMED a.s. is involved in the fight against the Covid-19 pandemic. In cooperation with Protean s.r.o. and Institute of Molecular and...
Successful completion of the OPPIK project ” Transfer factor – research and development of a new dosage form of immunotherapeutic medicinal product “
This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “Transfer factor – research and...
Successful completion of the OPPIK project “RESEARCH AND DEVELOPMENT OF A NEW WHOLE-CELL VACCINE AGAINST WHOOPING COUGH”
This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “RESEARCH AND DEVELOPMENT OF A...
Achievements in current grants
The project of innovative vaccine against whooping cough is in the terminal phase. The priority is the research and development...
Pharmaceutical production
AUMED is preparing the production of a mass-produced medical product. Under the contract manufacturing regime, AUMED wants to become a...
Research and development of a new oral administration of the vaccine in the company AUMED, a.s.
As part of the 4th public tender in the TRIO program, AUMED has a project for a new version of...
